Key result
MCS supports 100% initial survival during noncardiac surgery in high-risk cardiogenic shock.
Why the study?
A rising number of heart failure patients face high perioperative risk during surgical interventions, prompting an analysis of mechanical circulatory support value during non-cardiac surgery.
Does mechanical circulatory support improve survival in patients with severe heart failure undergoing non-cardiac surgery?
Observational (n=5)
No
Does mechanical circulatory support improve survival in patients with severe heart failure undergoing non-cardiac surgery?
Mechanical circulatory support is a feasible strategy to enable high-risk non-cardiac surgery in patients with severe heart failure or cardiogenic shock.
Supports feasibility of mechanical circulatory support for non-cardiac surgery in severe heart failure; leaves open survival benefit.
Background The prevalence of heart failure and the rate of surgical interventions are increasing worldwide, leading to a rising number of patients with heart failure who are at high perioperative risk. We analyzed the value of mechanical circulatory support (MCS) in patients with severe cardiac impairment who underwent non-cardiac surgery. Methods Single center retrospective analysis of 5 patients undergoing non-cardiac surgery (NCS) protected by MCS. Results Four patients with cardiogenic shock underwent NCS (gland resection, n = 4) protected by veno-arterial extracorporeal membrane oxygenation and an Impella CP microaxial pump. Elective Surgical thyroidectomy under hemodynamic protection with Impella CP was performed in one patient with severe chronic heart failure. All patients initially survived the surgery, and mechanical circulatory support led to rapid lactate clearance. One patient died during follow-up due to advanced multiorgan failure, the remaining four patients could be successfully weaned from hemodynamic circulatory support. Notably, the patient with fatal outcome s had the longest delay between the onset of cardiogenic shock and initiation of MCS, while other patients with elective or rapid (<24 h) implantation of mechanical circulatory support had favorable outcomes. Conclusions MCS is a promising strategy in cardiogenic shock, enabling hemodynamic stabilization and protected surgery. Rapid initiation of MCS is important. This approach may be viable for selected patients with severe heart failure who require elective NCS. Findings are preliminary and hypothesis-generating, further validation is needed.
No takes yet. Share an insight, caveat, or question.
Pfeffer et al. (2026) conducted an observational in Severe heart failure or cardiogenic shock requiring non-cardiac surgery (n=5). Mechanical circulatory support (Impella CP with or without VA-ECMO) was evaluated on Survival of surgery. Mechanical circulatory support enabled 100% initial survival of non-cardiac surgery in 5 patients with severe heart failure or cardiogenic shock, with 4 patients successfully weaned.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: